Overview
Inogen Q3 revenue grows 4% yr/yr, beating analyst expectations
Adjusted EBITDA for Q3 beats analyst estimates, reflecting improved operational performance
Company reiterates full-year revenue guidance, raises adjusted EBITDA outlook
Outlook
Inogen reiterates full-year revenue guidance of $354 mln to $357 mln
Company raises full-year adjusted EBITDA guidance to approximately $2 mln
Inogen expects Q4 revenue between $87 mln and $90 mln
Result Drivers
BUSINESS-TO-BUSINESS SALES - Increased demand from international and domestic B2B customers drove revenue growth
COST MANAGEMENT - Decrease in operating expenses due to ongoing cost management efforts
NEW PRODUCT RELEASE - Initiated limited market release of Simeox airway clearance device in the U.S.
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $92.40 mln | $92.20 mln (2 Analysts) |
Q3 Adjusted Net Income | Beat | -$500,000 | -$5.90 mln (2 Analysts) |
Q3 Net Income | -$5.30 mln | ||
Q3 Adjusted EBITDA | Beat | $2.30 mln | $750,000 (2 Analysts) |
Q3 Gross Margin | 44.70% |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Inogen Inc is $13.00, about 38% above its November 4 closing price of $8.06
Press Release: ID:nBwbfSmGSa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)